Lipigon Pharmaceuticals AB (publ) (LPGO.ST)
SEK 0.12
(-0.84%)
SEK 0.12
(-0.84%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -12.1 Million SEK | 66.69% |
| 2022 | -37.68 Million SEK | 8.29% |
| 2021 | -41.09 Million SEK | -425.79% |
| 2020 | - SEK | -60.06% |
| 2019 | - SEK | -29.56% |
| 2018 | - SEK | 99.88% |
| 2017 | -3.03 Billion SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -319 Thousand SEK | 95.26% |
| 2024 Q1 | -7.4 Million SEK | 1.85% |
| 2023 FY | - SEK | 66.69% |
| 2023 Q2 | 7.14 Million SEK | 204.55% |
| 2023 Q1 | -6.82 Million SEK | 25.69% |
| 2023 Q4 | -7.41 Million SEK | -52.6% |
| 2023 Q3 | -4.86 Million SEK | -168.08% |
| 2022 Q3 | -6.83 Million SEK | 45.94% |
| 2022 Q4 | -9.19 Million SEK | -34.51% |
| 2022 Q2 | -12.63 Million SEK | -40.17% |
| 2022 Q1 | -9.01 Million SEK | 37.45% |
| 2022 FY | - SEK | 8.29% |
| 2021 FY | - SEK | -425.79% |
| 2021 Q2 | -10.37 Million SEK | -112.38% |
| 2021 Q4 | -14.41 Million SEK | -26.07% |
| 2021 Q1 | -4.88 Million SEK | -4.16% |
| 2021 Q3 | -11.43 Million SEK | -10.21% |
| 2020 Q1 | -891 Thousand SEK | 0.0% |
| 2020 FY | - SEK | -60.06% |
| 2020 Q4 | -4.69 Million SEK | -611.68% |
| 2020 Q3 | -659 Thousand SEK | 57.78% |
| 2020 Q2 | -1.56 Million SEK | -75.2% |
| 2019 FY | - SEK | -29.56% |
| 2018 FY | - SEK | 99.88% |
| 2017 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 96.709% |
| Camurus AB (publ) | 562.54 Million SEK | 102.152% |
| Mendus AB (publ) | -97.84 Million SEK | 87.63% |
| Lipum AB (publ) | -37.11 Million SEK | 67.391% |
| NextCell Pharma AB | -40.98 Million SEK | 70.467% |
| Simris Alg AB (publ) | -22.36 Million SEK | 45.875% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | 29.152% |
| Active Biotech AB (publ) | -43.88 Million SEK | 72.42% |
| Amniotics AB (publ) | -27.14 Million SEK | 55.407% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | 14.862% |
| BioArctic AB (publ) | 275.38 Million SEK | 104.395% |
| Cantargia AB (publ) | -284.31 Million SEK | 95.743% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | 38.179% |
| CombiGene AB (publ) | -35.33 Million SEK | 65.746% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 91.407% |
| Genovis AB (publ.) | 64.57 Million SEK | 118.745% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 89.466% |
| Isofol Medical AB (publ) | -37.02 Million SEK | 67.308% |
| Intervacc AB (publ) | -68.98 Million SEK | 82.453% |
| Kancera AB (publ) | -61.88 Million SEK | 80.442% |
| Karolinska Development AB (publ) | -26.78 Million SEK | 54.807% |
| LIDDS AB (publ) | -39.67 Million SEK | 69.488% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 138.543% |
| OncoZenge AB (publ) | 7.26 Million SEK | 266.584% |
| Saniona AB (publ) | -69.69 Million SEK | 82.633% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 96.187% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 95.708% |
| Xintela AB (publ) | -53.47 Million SEK | 77.363% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 92.872% |
| Ziccum AB (publ) | -20.34 Million SEK | 40.497% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 605300.0% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 94.906% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -481.923% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | 9.88% |
| Corline Biomedical AB | -1.69 Million SEK | -615.789% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 93.017% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | 77.915% |
| Aptahem AB (publ) | -10 Million SEK | -20.928% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 204.806% |
| Fluicell AB (publ) | -25.91 Million SEK | 53.292% |
| Biovica International AB (publ) | -119.5 Million SEK | 89.872% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 71.334% |
| AcouSort AB (publ) | -16.7 Million SEK | 27.534% |
| Abliva AB (publ) | -93.6 Million SEK | 87.069% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 96.207% |
| 2cureX AB (publ) | -35.13 Million SEK | 65.551% |
| I-Tech AB | 30.34 Million SEK | 139.888% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 98.306% |
| Cyxone AB (publ) | -20.41 Million SEK | 40.707% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 88.186% |
| Biosergen AB | 228 Thousand SEK | 5408.772% |
| Nanologica AB (publ) | -62.11 Million SEK | 80.515% |
| SynAct Pharma AB | -222.7 Million SEK | 94.565% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | 72.404% |
| BioInvent International AB (publ) | -312.7 Million SEK | 96.129% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 4011.924% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 28919.734% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 94.774% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -37.351% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 88.85% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -5.537% |